#United States #New York #Securities Fraud #Pomerantz LLP #Omeros Corporation

Pomerantz Law Firm Investigates Omeros Corporation for Possible Claims

On July 16, 2026, the Pomerantz Law Firm, a leading legal firm known for its corporate and securities litigation, announced an investigation regarding possible securities fraud associated with Omeros Corporation (NASDAQ: OMER). The firm aims to represent investors who might have been adversely affected by the company’s recent disclosures and subsequent market reactions.

The investigation follows a crucial press release from Omeros on June 26, 2026, where the company revealed negative feedback from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency concerning its application for marketing authorization of narsoplimab. This treatment was intended for patients suffering from hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Despite the representation of Omeros alongside four international experts during the review process, the CHMP adopted a negative opinion on the marketing application.

The consequences of this news were immediate and severe. On the same day, Omeros's share price plummeted by $2.05, reflecting a staggering 19.12% drop to close at $8.67 per share. This significant decline raises questions about potential misrepresentations or failures in disclosing relevant information to investors by the company's executives and directors.

Why This Matters for Investors

The implications of these developments are significant for current and potential investors in Omeros. The investigation highlights concerns that the corporate governance practices within Omeros may not align with the best interests of its investors, which could potentially stem from misconduct. Such a scenario could have legally enforceable ramifications, especially if it’s determined that there were indeed harmful fraudulent activities impacting the company's stock.

Pomerantz LLP, founded over 85 years ago, has built a reputation as a formidable advocate for investors in cases of securities fraud, claims of wrongdoing by corporate executives, and violations of fiduciary duties. The firm has successfully recovered millions in damages for its clients and victims of corporate misconduct. With offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, its reach and resources provide robust representation for those affected.

For investors feeling unsure about their position with Omeros, it is suggested that they reach out for consultation. Danielle Peyton, a representative from Pomerantz, is available at [email protected] or via phone at 646-581-9980, ext. 7980, for anyone looking to learn more about participating in a potential class-action lawsuit. The firm’s expertise could offer crucial support to those disputing the impact of Omeros’s recent developments on their investments.

Background on Omeros Corporation

Founded with the mission of empowering patients and ameliorating severe medical conditions, Omeros has made significant strides in developing therapies targeting serious diseases. However, the recent adverse opinions from regulatory bodies raise concerns over its operational integrity and transparency. Investors must stay alert for updates and ensure that their interests are adequately represented.

In conclusion, the ongoing investigations into Omeros highlight the fragility of investor confidence in the pharmaceutical sector, especially regarding regulatory compliance and ethical business practices. With the financial stakes so high, vigilance and legal support through reputable legal firms like Pomerantz are essential for safeguarding investor rights and interests.

This situation serves as a reminder of the importance of accountability in corporate governance and the indispensable role of legal entities in championing investor protection.